Data supports theory that RSBT-001 can positively impact damaging inflammation without eliminating beneficial immune response CUMBERLAND, Md. – July 11, 2022 – RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is […]
Learn about the endocannabinoid system and endocannabinoid deficiency in our archive of medical cannabis articles and interviews. Human understanding of the endocannabinoid system is still being developed, and cannabis has been proven as a viable medical treatment for a wide variety of conditions due to its effects on this system.
